- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract illness (LRTI) caused by RSV
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 268KB)
Respiratory Syncytial Virus Vaccine – November 2024
Respiratory Syncytial Virus Vaccine; Injection (0.5 mL);Abrysvo®
Last updated
5 June 2025